Clinical Scorecard: Confronting the Messy Reality of PFAS Regulation

At a Glance

Key Highlights

• PFAS regulation is fragmented across different agencies with varying targets and methods.
• There are thousands of PFAS compounds, with only a small number linked to toxicity.
• The cycle of 'regrettable substitutions' leads to continuous replacement of harmful PFAS with new ones.
• Europe is considering a conservative approach to ban all PFAS as a single class.
• Public perception often mischaracterizes chemicals, overlooking their essential roles.

Guideline-Based Recommendations

Diagnosis

• Conduct non-targeted analysis to identify PFAS in the environment.

Management

• Adopt a unified regulatory approach to assess and monitor PFAS risks.

Monitoring & Follow-up

• Implement routine testing for a broader range of PFAS compounds.

Risks

• Assume PFAS are risky until proven otherwise due to their persistence and potential toxicity.

Patient & Prescribing Data

Individuals potentially exposed to PFAS through water, food, and consumer products.

Focus on responsible use and regulation of PFAS in essential applications.

Clinical Best Practices

• Encourage collaboration among regulatory agencies to standardize PFAS testing and regulation.
• Promote public education on the role and risks of chemicals, including PFAS.

References

• Buck et al. 2021
• OECD Report
• US EPA Databases
• Szymanski et al. 2023